IMMX
Immix Biopharma Inc (IMMX)
Healthcare • NASDAQ • $13.19-0.30%
Key Fundamentals
- Symbol
- IMMX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $13.19
- Daily Change
- -0.30%
- Market Cap
- $780.95M
- Trailing P/E
- N/A
- Forward P/E
- -12.14
- 52W High
- $12.14
- 52W Low
- $1.94
- Analyst Target
- $20.28
- Dividend Yield
- N/A
- Beta
- 0.11
About Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Company websiteResearch IMMX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.